论文部分内容阅读
年龄相关性黄斑变性(AMD)是老年人群主要的致盲眼病,主要影响患者的视网膜色素上皮细胞(RPE)及光感受器,导致患者中心视力进行性丧失.AMD分为干性AMD和湿性AMD 2种类型,目前临床上对于AMD的治疗主要针对湿性AMD伴发的脉络膜新生血管(CNV),而对于干性AMD尚无有效的治疗方法.AMD常见的治疗方法主要包括光动力疗法(PDT)和玻璃体腔注射抗血管内皮生长因子(VEGF)药物治疗,此外还有激光治疗、放射疗法和手术治疗等,然而现阶段的临床治疗均无法根除病因,且部分患者对治疗反应差,因此人们开始探索新的AMD治疗方法.其中,间充质干细胞(MSCs)治疗具有自我更新和多向分化潜能、低免疫原性和取材方便、伦理道德方面约束较少的特点,展现出了广阔的治疗前景.目前,国内外相继开展了许多利用MSCs治疗AMD的研究,成果颇丰.本文阐述了AMD的分型和治疗现状及其局限性,并对近年来国内外针对MSCs治疗AMD的研究成果进行综述.“,”Age-related macular degeneration (AMD) is the major cause of blindness in the elderly,which mainly affects the retinal pigment epithelial ( RPE) cells and photoreceptors,and progressively leads to the loss of central vision. AMD can be divided into dry AMD and wet AMD. At present,the treatment of AMD mainly aims at choroidal neovascularization ( CNV) associated with wet AMD. However,there is no effective treatment for dry AMD. The common treatment methods include photodynamic therapy ( PDT ) and intravitreal injection of anti-vascular endothelial growth factor (VEGF). Furthermore,there are also laser therapy,radiotherapy and surgical treatment. However,at this stage, the clinical treatment methods can not eradicate the causes, and some patients show poor response to treatments. So people began to explore new treatments. Mesenchymal stem cells ( MSCs) therapy has the characteristics of self-renewal and multidirectional differentiation potential, lower immunogenicity, easier access to materials and less ethical constraints,showing a broad therapeutic prospect. At present,many studies on the treatment of AMD with MSCs have been carried out at home and abroad, with fruitful results. This article elaborated the classification and treatment status of AMD and their limitations and summarized the research results of MSCs in the treatment of AMD at home and abroad in recent years.